Microbiotix, Inc. - Product Pipeline Review - 2016

Published: Mar, 2016 | Pages: 52 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Microbiotix, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Microbiotix, Inc. - Product Pipeline Review - 2016', provides an overview of the Microbiotix, Inc.'s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Microbiotix, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Microbiotix, Inc.
- The report provides overview of Microbiotix, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Microbiotix, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Microbiotix, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to Buy

- Evaluate Microbiotix, Inc.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Microbiotix, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Microbiotix, Inc.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Microbiotix, Inc. Snapshot 7
Microbiotix, Inc. Overview 7
Key Information 7
Key Facts 7
Microbiotix, Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Microbiotix, Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Microbiotix, Inc. - Pipeline Products Glance 13
Microbiotix, Inc. - Clinical Stage Pipeline Products 13
Phase I Products/Combination Treatment Modalities 13
Microbiotix, Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Microbiotix, Inc. - Drug Profiles 16
filociclovir 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
MBX-700 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
MBX-500 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
MBX-701 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
MBX-900 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Small Molecules to Inhibit 16S rRNA for Tuberculosis 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Small Molecules to Inhibit T3SS for Pseudomonas Aeruginosa Infections 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
KKL-35 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
MBX-2168 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
MBX-2319 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
MBX-2329 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
MBX-2359 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
MBX-2402 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
MBX-2546 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecule to Inhibit DNA Helicase for Infectious Diseases 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecules for Ebola Virus Infection 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecules for Fungal Infections 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecules for Gram-Negative Bacterial Infections 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules to Inhibit bNOS for MRSA Infections 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules to Inhibit BoNT/A LC for Botulism 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecules to Inhibit DNA Synthesis for Gram-Negative and Gram-Positive Bacterial Infections 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecules to Inhibit NPC1 for Filovirus Infections 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecules to Inhibit PSAC for Malaria 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecules to Inhibit the Fatty Acid Synthesis II for Pseudomonas Aeruginosa Infections 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Microbiotix, Inc. - Pipeline Analysis 45
Microbiotix, Inc. - Pipeline Products by Target 45
Microbiotix, Inc. - Pipeline Products by Route of Administration 46
Microbiotix, Inc. - Pipeline Products by Molecule Type 47
Microbiotix, Inc. - Pipeline Products by Mechanism of Action 48
Microbiotix, Inc. - Dormant Projects 49
Microbiotix, Inc. - Locations And Subsidiaries 50
Head Office 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 51
Disclaimer 52

List of Tables

Microbiotix, Inc., Key Information 7
Microbiotix, Inc., Key Facts 7
Microbiotix, Inc. - Pipeline by Indication, 2016 9
Microbiotix, Inc. - Pipeline by Stage of Development, 2016 11
Microbiotix, Inc. - Monotherapy Products in Pipeline, 2016 12
Microbiotix, Inc. - Phase I, 2016 13
Microbiotix, Inc. - Preclinical, 2016 14
Microbiotix, Inc. - Discovery, 2016 15
Microbiotix, Inc. - Pipeline by Target, 2016 45
Microbiotix, Inc. - Pipeline by Route of Administration, 2016 46
Microbiotix, Inc. - Pipeline by Molecule Type, 2016 47
Microbiotix, Inc. - Pipeline Products by Mechanism of Action, 2016 48
Microbiotix, Inc. - Dormant Developmental Projects,2016 49